dapt (insolution™ γ-secretase inhibitor ix  (Merck KGaA)

Journal: Open Life Sciences

Article Title: Transfer RNA-derived fragment tRF-36 modulates varicose vein progression via human vascular smooth muscle cell Notch signaling

doi: 10.1515/biol-2025-1075

Figure Lengend Snippet: Cell transfection efficiency and selection of the optimal DAPT concentration. (a) The level of tRF-36 in the varicose vein tissues measured by RT-qPCR. * P < 0.05 compared to ANV. (b) The expression level of tRF-36 after cell transfection detected by RT-qPCR. * P < 0.05 compared to mimic NC and # P < 0.05 compared to inhibitor NC. The expression of Notch 1 (c), 2 (d), and 3 (e) after cells treated with different concentrations of DAPT. * P < 0.05 compared to control, # P < 0.05 compared to DAPT 2.5, and $ P < 0.05 compared to DAPT 5.

Article Snippet: To select the optimal concentration of a kind of γ-secretase inhibitor GSI-IX (DAPT) (Notch signaling pathway inhibitor; Selleck, Houston, TX, USA; # S2215), different concentrations of DAPT (0, 2.5, 5, 10, or 20 μM) were used to treat the HVSMCs with 0 μM DAPT as the control, and the expression of Notch 1, 2, and 3 were measured using RT-qPCR.

Techniques: Transfection, Selection, Concentration Assay, Quantitative RT-PCR, Expressing, Control

Journal: Open Life Sciences

Article Title: Transfer RNA-derived fragment tRF-36 modulates varicose vein progression via human vascular smooth muscle cell Notch signaling

doi: 10.1515/biol-2025-1075

Figure Lengend Snippet: Effects of Notch pathway on the growth of HVSMCs. (a) The mRNA expression of tRF-36 after cells treated with DAPT detected by RT-qPCR. (b) The viability of HVSMCs after cell transfection or DAPT treatment detected by CCK-8. The mRNA expression of SMA-α (c) and SM22α (d) after cell transfection or DAPT treatment detected by RT-qPCR. * P < 0.05 compared to the DMSO group, # P < 0.05 compared to the DAPT group, and $ P < 0.05 compared to the tRF-36 mimics group.

Article Snippet: To select the optimal concentration of a kind of γ-secretase inhibitor GSI-IX (DAPT) (Notch signaling pathway inhibitor; Selleck, Houston, TX, USA; # S2215), different concentrations of DAPT (0, 2.5, 5, 10, or 20 μM) were used to treat the HVSMCs with 0 μM DAPT as the control, and the expression of Notch 1, 2, and 3 were measured using RT-qPCR.

Techniques: Expressing, Quantitative RT-PCR, Transfection, CCK-8 Assay

Journal: Turkish Journal of Biology

Article Title: Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer

doi: 10.55730/1300-0152.2663

Figure Lengend Snippet: (A) The tumor volume and (B) body weight changes of Carrier 1, Carrier 2, DAPT, Anakinra and Allo aca treatments on the HCT-15 tumor-bearing mice. Data is shown as mean ± SE derived from a minimum of three independent experiments. * p < 0.05, ** p < 0.01, and ***p < 0.001.

Article Snippet: γ-secretase inhibitor DAPT (GSI-IX) was purchased from Selleckchem (Cat No. 208255-80-5, Houston, TX, USA), IL-1 receptor antagonist Anakinra was purchased from TOCRIS (Cat No. 185413-30-3, Minneapolis, MN, USA) and the leptin receptor antagonist, Allo aca, was purchased from Peptides international (Cat No. PCS-32627-PI, Louisville, Kentucky, USA).

Techniques: Derivative Assay

Journal: Turkish Journal of Biology

Article Title: Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer

doi: 10.55730/1300-0152.2663

Figure Lengend Snippet: mRNA levels of NOTCH1 receptor, JAGGED1 ligand, IL-1β and IL-1R, LEPTIN, ObRb, VEGF-A, VEGFR1, and VEGFR2 (A-B-C-D-E-F-G-H-I respectively) in the γ-secretase inhibitor DAPT treatment group in CRC tumors. Levels of mRNA determined by real-time RT-PCR. β-actin was used as an internal control. Data is shown as mean ± SE derived from a minimum of three independent experiments. * p < 0.05, ** p < 0.01, and ***p < 0.001.

Article Snippet: γ-secretase inhibitor DAPT (GSI-IX) was purchased from Selleckchem (Cat No. 208255-80-5, Houston, TX, USA), IL-1 receptor antagonist Anakinra was purchased from TOCRIS (Cat No. 185413-30-3, Minneapolis, MN, USA) and the leptin receptor antagonist, Allo aca, was purchased from Peptides international (Cat No. PCS-32627-PI, Louisville, Kentucky, USA).

Techniques: Quantitative RT-PCR, Control, Derivative Assay

Journal: Turkish Journal of Biology

Article Title: Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer

doi: 10.55730/1300-0152.2663

Figure Lengend Snippet: Immuno-histochemical analysis of NOTCH1 protein expression in tumor tissues. Strong cytoplasmic NOTCH1 immuno-reactivity (arrows) throughout the tumor cells in Carrier 1 and Carrier 2 receiving tumors, and weak cytoplasmic NOTCH1 immuno-reactivity in a small number of tumor cells in the DAPT, Anakinra and Allo aca treated tumors (DAB-Hematoxylin, ×400). * p < 0.05, ** p < 0.01, and ***p < 0.001.

Article Snippet: γ-secretase inhibitor DAPT (GSI-IX) was purchased from Selleckchem (Cat No. 208255-80-5, Houston, TX, USA), IL-1 receptor antagonist Anakinra was purchased from TOCRIS (Cat No. 185413-30-3, Minneapolis, MN, USA) and the leptin receptor antagonist, Allo aca, was purchased from Peptides international (Cat No. PCS-32627-PI, Louisville, Kentucky, USA).

Techniques: Expressing

Journal: Turkish Journal of Biology

Article Title: Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer

doi: 10.55730/1300-0152.2663

Figure Lengend Snippet: Immuno-histochemical analysis of IL-1α protein expression in tumor tissues. (A) Macrophages (black arrow) and lymphocytes (yellow arrow) show strong cytoplasmic IL-1α immune-reactivity in Carrier 1 and Carrier 2 receiving tumors, and weak immune-reaction in the DAPT, Anakinra and Allo aca treated tumors. (B) Strong cytoplasmic IL-1α immune-reactivity (arrowhead) in most tumor cells in Carrier 1 and Carrier 2 receiving tumors, and weak cytoplasmic IL-1α immunoreaction in a small number of tumor cells in the DAPT, Anakinra and Allo aca treated tumors (DAB-Hematoxylin, ×400). * p < 0.05, ** p < 0.01, and ***p < 0.001.

Article Snippet: γ-secretase inhibitor DAPT (GSI-IX) was purchased from Selleckchem (Cat No. 208255-80-5, Houston, TX, USA), IL-1 receptor antagonist Anakinra was purchased from TOCRIS (Cat No. 185413-30-3, Minneapolis, MN, USA) and the leptin receptor antagonist, Allo aca, was purchased from Peptides international (Cat No. PCS-32627-PI, Louisville, Kentucky, USA).

Techniques: Expressing

Journal: Turkish Journal of Biology

Article Title: Targeting of Notch, IL-1, and leptin has therapeutic potential in xenograft colorectal cancer

doi: 10.55730/1300-0152.2663

Figure Lengend Snippet: Immuno-histochemical analysis of IL-1β protein expression in tumor tissues. (A) Macrophages (black arrow) and lymphocytes (yellow arrow) show strong cytoplasmic IL-1β immuno-reaction in Carrier 1 and Carrier 2 receiving groups tumors and weak immuno-reaction in DAPT, Anakinra and Allo aca groups. (B) Strong cytoplasmic IL-1β immune-reaction (arrowhead) in most tumor cells in Carrier 1 and Carrier 2 receiving groups’ tumors and weak cytoplasmic IL-1β immune-reaction in a small number of tumor cells in the DAPT, Anakinra and Allo aca treated tumors (DAB-Hematoxylin, ×400). * p < 0.05, ** p < 0.01, and ***p < 0.001.

Article Snippet: γ-secretase inhibitor DAPT (GSI-IX) was purchased from Selleckchem (Cat No. 208255-80-5, Houston, TX, USA), IL-1 receptor antagonist Anakinra was purchased from TOCRIS (Cat No. 185413-30-3, Minneapolis, MN, USA) and the leptin receptor antagonist, Allo aca, was purchased from Peptides international (Cat No. PCS-32627-PI, Louisville, Kentucky, USA).

Techniques: Expressing